• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 3: New insider Ffi Fund Ltd claimed ownership of 2,229,855 units of Common Stock

    9/17/21 4:18:08 PM ET
    $BLUWU
    Business Services
    Finance
    Get the next $BLUWU alert in real time by email
    SEC FORM 3 SEC Form 3
    FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0104
    Estimated average burden
    hours per response: 0.5
    1. Name and Address of Reporting Person*
    FFI FUND LTD

    (Last) (First) (Middle)
    C/O BRACEBRIDGE CAPITAL, LLC
    888 BOYLSTON STREET, 15TH FLOOR

    (Street)
    BOSTON MA 02199

    (City) (State) (Zip)
    2. Date of Event Requiring Statement (Month/Day/Year)
    09/09/2021
    3. Issuer Name and Ticker or Trading Symbol
    Clarus Therapeutics Holdings, Inc. [ CRXT ]
    4. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    Director X 10% Owner
    Officer (give title below) Other (specify below)
    5. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    Form filed by One Reporting Person
    X Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Beneficially Owned
    1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
    Common Stock 2,229,855 I See footnotes(1)(2)
    Table II - Derivative Securities Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
    Date Exercisable Expiration Date Title Amount or Number of Shares
    1. Name and Address of Reporting Person*
    FFI FUND LTD

    (Last) (First) (Middle)
    C/O BRACEBRIDGE CAPITAL, LLC
    888 BOYLSTON STREET, 15TH FLOOR

    (Street)
    BOSTON MA 02199

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    FYI Ltd

    (Last) (First) (Middle)
    C/O BRACEBRIDGE CAPITAL, LLC
    888 BOYLSTON STREET, 15TH FLOOR

    (Street)
    BOSTON MA 02199

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Olifant Fund, Ltd.

    (Last) (First) (Middle)
    C/O BRACEBRIDGE CAPITAL, LLC
    888 BOYLSTON STREET, 15TH FLOOR

    (Street)
    BOSTON MA 02199

    (City) (State) (Zip)
    1. Name and Address of Reporting Person*
    Bracebridge Capital, LLC

    (Last) (First) (Middle)
    888 BOYLSTON STREET, 15TH FLOOR

    (Street)
    BOSTON MA 02199

    (City) (State) (Zip)
    Explanation of Responses:
    1. 2,229,855 of the total reported shares of common stock, $0.0001 par value per share ("Common Stock"), of the Issuer are owned directly as follows: (i) 1,627,795 shares of Common Stock are owned directly by FFI Fund Ltd. ("FFI"), (ii) 312,179 shares of Common Stock are owned directly by FYI Ltd. ("FYI"), and (iii) 289,881 shares of Common Stock are owned directly by Olifant Fund, Ltd. (together with FFI and FYI, the "Bracebridge Funds"). Bracebridge Capital, LLC (the "Investment Manager") is the investment manager of each of the Bracebridge Funds, and has the authority to vote and dispose of all the shares of Common Stock reflected herein.
    2. Each of the Bracebridge Funds and the Investment Manager disclaims beneficial ownership of the shares of Common Stock except to the extent of any pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Persons are the beneficial owners of the shares of Common Stock reported herein for purposes of Section 16 of the Securities Exchange Act of 1934 or for any other purpose.
    /s/ FFI Fund Ltd., By Gabriel Sunshine, Authorized Representative 09/17/2021
    /s/ FYI Ltd., By Gabriel Sunshine, Authorized Representative 09/17/2021
    /s/ Olifant Fund, Ltd., By Gabriel Sunshine, Authorized Representative 09/17/2021
    /s/ Bracebridge Capital, LLC, By Gabriel Sunshine, Authorized Representative 09/17/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BLUWU alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BLUWU

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BLUWU
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Blue Water Acquisition Corp. (Amendment)

      SC 13G/A - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      10/8/21 4:24:24 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13G filed by Blue Water Acquisition Corp.

      SC 13G - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/24/21 6:06:39 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form SC 13D filed by Blue Water Acquisition Corp.

      SC 13D - Clarus Therapeutics Holdings, Inc. (0001817944) (Subject)

      9/21/21 4:18:31 PM ET
      $BLUWU
      Business Services
      Finance

    $BLUWU
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: H.I.G. Ventures - Clarus, Llc was granted 5,692,381 shares

      4 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:09:50 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3 filed by new insider H.I.G. Ventures - Clarus, Llc

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      10/4/21 4:07:54 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 3: New insider Cbc Spvi Ltd claimed ownership of 3,602,287 units of Common Stock

      3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Issuer)

      9/24/21 6:05:09 AM ET
      $BLUWU
      Business Services
      Finance

    $BLUWU
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Blue Water Acquisition Corp. III Announces Closing of Upsized $253 Million Initial Public Offering

      GREENWICH, Conn., June 11, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company") (NASDAQ:BLUWU), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the closing of its upsized initial public offering of 25,300,000 units, which includes 3,300,000 units issued pursuant to the full exercise by the underwriters of their over-allotment option, at an offering price of $10.00 per unit, resulting in gross proceeds of $253,000,000. The Company'

      6/11/25 1:24:00 PM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. III Announces the Upsized Pricing of $220 Million Initial Public Offering

      GREENWICH, Conn., June 10, 2025 /PRNewswire/ -- Blue Water Acquisition Corp. III (the "Company"), a newly organized special purpose acquisition company formed as a Cayman Islands exempted company and led by Chairman and Chief Executive Officer Joseph Hernandez, today announced the upsized pricing of its initial public offering of 22,000,000 units at an offering price of $10.00 per unit, with each unit consisting of one Class A ordinary share and one-half of one redeemable warrant. Each whole warrant will entitle the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share. The units are expected to trade on The Nasdaq Global Market ("Nasdaq")under the ticker symbo

      6/10/25 6:00:00 AM ET
      $BLUWU
      Business Services
      Finance
    • Blue Water Acquisition Corp. Announces Stockholder Approval of Business Combination with Clarus Therapeutics, Inc.

      GREENWICH, Conn., Aug. 27, 2021 (GLOBE NEWSWIRE) -- Blue Water Acquisition Corp. (NASDAQ:BLUW), a special purpose acquisition company ("Blue Water"), today announced that its stockholders have voted to approve the proposed business combination (the "Business Combination") with Clarus Therapeutics, Inc., a pharmaceutical company dedicated to providing solutions to unmet medical needs by advancing androgen and metabolic therapies for men and women ("Clarus") at its special meeting of stockholders (the "Special Meeting") held today, August 27, 2021. Holders of approximately 73.95% of Blue Water's issued and outstanding shares cast votes at the Special Meeting. Approximately 69.57% o

      8/27/21 12:58:37 PM ET
      $BLUW
      $BLUWU
      Business Services
      Finance

    $BLUWU
    SEC Filings

    See more
    • SEC Form EFFECT filed by Blue Water Acquisition Corp.

      EFFECT - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/8/21 12:15:18 AM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form 424B3 filed by Blue Water Acquisition Corp.

      424B3 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      10/7/21 5:07:36 PM ET
      $BLUWU
      Business Services
      Finance
    • SEC Form S-1 filed by Blue Water Acquisition Corp.

      S-1 - Clarus Therapeutics Holdings, Inc. (0001817944) (Filer)

      9/30/21 4:07:33 PM ET
      $BLUWU
      Business Services
      Finance